Related Experiment Video

Updated: Jun 28, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas

Niveen Shibli1, Sigrun Einarsdottir2, Teng Fei3

  • 1Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Transplantation and Cellular Therapy
|June 26, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Chimeric antigen receptor T (CAR-T) cell therapyrelapsed or refractory (R/R) B-cell malignanciessplenectomized patients

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jun 28, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Articles linked to this work by shared authors, journal, and citation graph.

ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy.

Transplantation and cellular therapy·2026

Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Blood cancer discovery·2026

Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma.

JCO oncology practice·2026

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Cancer·2026

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus.

Cancer·2026

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Leukemia·2026

Trends and Predictors of Hematopoietic Cell Transplant Utilization for HIV-lymphoma in California, 1991-2016.

Transplantation and cellular therapy·2026

Risk Factors for Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation Using Rabbit Anti-thymocyte Globulin or Porcine Anti-human T Lymphocyte Immunoglobulin in the Letermovir Era.

Transplantation and cellular therapy·2026

Early prophylactic rituximab reduces EBV infection and PTLD in high-risk patients receiving allogeneic hematopoietic stem cell transplantation.

Transplantation and cellular therapy·2026

Early Broad-Spectrum Antibiotic Exposure Is Associated with Increased Relapse after Myeloablative TBI-Based Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026

Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

Transplantation and cellular therapy·2026

HLA-DPB1 TCE mismatch vector differentially affects HCT outcomes in 10/10 and ≤9/10 HLA matched patients in the UK.

Transplantation and cellular therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us